CA-GLOBALLOGIC
30.11.2021 13:30:05 CET | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Cybereason, the leader in operation-centric attack protection, to help develop its next-generation cyber security platform and services. Deployed by large enterprises, governments, and major cloud providers worldwide, Cybereason’s future-ready attack protection spans across endpoints, the enterprise, the cloud, and everywhere the defenders battle cyber criminals. The collaboration will draw on GlobalLogic’s broad and deep expertise in security and data management software across devices through to the cloud, including the integration of advanced artificial intelligence (AI).
The program is one of the largest won by GlobalLogic in this field to date. It requires quickly scaling to hundreds of specialized engineers supporting Cybereason’s development roadmap over the next year. This program scope highlights the market’s need for stronger, better cybersecurity as cloud use, network expansions and other technology usage continued their upward trend and surged during the pandemic.
“Cyber threats have become considerably more frequent and sophisticated in recent years. We’ve become dangerously more vulnerable in areas traditional security solutions could not adequately protect—the network and the cloud,” said Rajaram Radhakrishnan, CRO, GlobalLogic. “Having operated in the cybersecurity space for more than a decade, GlobalLogic has become adept at successfully responding to complex requirements. Cybereason is a premier example of a crucial innovator building disruptive defense solutions, redefining what government-grade protection can be. We are honored to now be a part of their team.”
Cybereason delivers the most comprehensive protection available on the market today, analyzing more than 23 trillion security-related events per week—five times the volume of any other market solution. Using its patented Malicious Operations (MalOps™) engine, Cybereason reveals the full attack story across every device, user identity, application, and cloud deployment. One of Cybereason’s key solutions delivering this capability is the company’s Extended Detection and Response (XDR) solution —a unified detection and response tool that thwarts malicious operations across the entire IT stack. XDR is one of the several advanced technologies that GlobalLogic’s team will help Cybereason develop and enhance through the partnership.
“Cybereason’ operation-centric security approach is helping defenders combat sophisticated and persistent threats to their organizations. While other companies have security analysts chasing alerts without offering valuable insight, Cybereason helps organizations around the world leverage our award-winning technology each day to outthink and outpace attackers,” said Sam Curry, Chief Security Officer, Cybereason. “GlobalLogic’s track record along with its responsiveness and collaborative approach to R&D stood out as major factors in finalizing our partnership. Together, we will deliver next-gen cyber defense solutions that will help technology users better control their sensitive data and operations—no matter where they reside.”
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
About Cybereason
Cybereason (www.cybereason.com ) is the champion for today’s cyber defenders, providing operation-centric attack protection that unifies security from the endpoint to the enterprise, to everywhere the battle moves. The Cybereason Defense Platform combines the industry’s top-rated AI-powered detection and response (EDR and XDR), next-gen antivirus (NGAV), Anti-Ransomware Protection and Proactive Threat Hunting to deliver context-rich analysis of every stage of a MalOp™ (malicious operation). Cybereason is a privately held, international company headquartered in Boston with customers in more than 40 countries.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005650/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
